Evaxion to present new biomarker data for ai-designed personalized cancer vaccine evx-01 at the sitc 2025 annual meeting

Copenhagen, denmark, october 3, 2025 - evaxion a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, will present new data for its lead asset evx-01 at a poster session at the society for immunotherapy of cancer (sitc) 2025 annual meeting taking place in national harbor november 5-9, 2025. designed with evaxion's ai-immunology™ platform, evx-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
EVAX Ratings Summary
EVAX Quant Ranking